Showing results (201-210 of 495) with videos related to
Sort By:
Pageof 50
JAMA|June 28, 2001
Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectivenessS J Goldie, L Kuhn, L Denny, et al.Journal of Pediatric Ophthalmology and Strabismus|November 1, 1991
Laser treatment of eye disorders in childrenA Pollack, H Leiba, D Soroker, et al.Urology|November 1, 1994
Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancerA Pollack, G K Zagars, A K el-Naggar, et al.Psychiatric Services (Washington, D.C.)|July 16, 2005
Outcomes of patients in a low-intensity, short-duration involuntary outpatient commitment programDavid A Pollack, Bentson H McFarland, Jo M Mahler, et al.Medical Care|January 17, 2007
The impact of managed care enrollment on emergency department use among children with special health care needsHarold A Pollack, John R C Wheeler, Anne Cowan, et al.Eye (London, England)|October 5, 2001
Optic nerve head blood flow measurements in non-arteritic anterior ischaemic optic neuropathyH Leiba, R Rachmiel, A Harris, et al.Cancer|April 1, 1994
The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapyG K Zagars, F B Geara, A Pollack, et al.The Journal of Urology|May 1, 1994
Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcomeG K Zagars, M E Sands, A Pollack, et al.Cancer|February 15, 1982
Active specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: effective treatment of BCG side effects with isoniazidM G Hanna, V A Pollack, L C Peters, et al.Urology|August 1, 1994
Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancerM E Sands, G K Zagars, A Pollack, et al.Pageof 50